FDA's New Class II Rule for Ceramic Hemi-Shoulder Implants

If you make, distribute, or are getting ready to submit a shoulder joint humeral (hemi-shoulder) ceramic head/metallic stem prosthesis, the rulebook you're working from changed on June 5, 2026. FDA published a final order classifying this device type into Class II, with a defined set of special controls, at 91 FR 34152 (Docket No. FDA-2026-N-5830). The new regulation lives at 21 CFR 888.3695.

The lesson here isn't really about the device itself. It's about what happens when a device that used to require a full De Novo request now has a clear, codified path that other manufacturers can follow. That's a meaningfully lower barrier to market for anyone building a competing or follow-on hemi-shoulder implant with a ceramic head and metallic stem, cemented or uncemented. It's also a signal about where FDA's evidentiary expectations for shoulder arthroplasty devices are heading, and those expectations are now spelled out in enough detail that you can build your test plan directly from the regulation.

What Actually Changed

Before this order, a ceramic head/metallic stem hemi-shoulder prosthesis had no dedicated classification regulation. The manufacturer that wanted to bring one to market had to petition FDA directly through the De Novo pathway under section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act, arguing from scratch that general controls plus a defined set of special controls would provide reasonable assurance of safety and effectiveness. FDA received that request on February 8, 2022, from Tornier SAS for its Tornier Pyrocarbon Humeral Head (product code HSD). FDA granted the request and classified the device into Class II by order on December 16, 2022. The June 5, 2026 final order is the codification step: per its statutory obligation, it writes that existing classification into 21 CFR 888.3695 so future devices of the same type don't have to repeat the argument.

That's the practical shift. Where there was once a single De Novo grant applicable to one device, there is now a standing regulation, 21 CFR 888.3695, that any manufacturer of a substantially equivalent device can point to. A second-generation or competitor hemi-shoulder implant with a ceramic head and metallic stem can now go through the 510(k) pathway under 21 CFR 807.81, citing the newly classified device type as a predicate, instead of running its own De Novo process. That is a materially faster and cheaper route to market, and it's the reason this classification action is worth reading closely even if you had no involvement in the original De Novo submission.

The Special Controls, and What They Actually Ask For

Class II status means general controls (establishment registration, device listing, labeling, good manufacturing practice under the Quality System Regulation) aren't enough on their own. FDA identified seven categories of special controls in the order, and they read less like abstract principles and more like a table of contents for your verification and validation plan.

None of that is exotic if you've submitted an orthopedic 510(k) before. What's notable is that FDA folded clinical performance data into the special controls list at all. A lot of Class II orthopedic hardware clears on bench testing and substantial equivalence alone. Here, the agency is telling you up front that mechanical testing won't carry the submission by itself, you need outcome data tied to shoulder function and a defined adverse event taxonomy. If you're scoping a submission strategy around this predicate, that's the line item that will drive your timeline and your budget more than any single bench test will.

Why FDA Landed on Class II Instead of Class III

The statutory test FDA applies here comes straight from section 513(a)(1) of the FD&C Act. A device goes to Class III when general and special controls together still can't provide reasonable assurance of safety and effectiveness, typically because it supports or sustains life, is implanted, or presents an unreasonable risk of illness or injury. FDA's order concludes the opposite for this device type: general controls alone are insufficient, but a defined set of special controls closes the gap. That's the textbook definition of Class II. It's worth stating plainly, because it's the kind of line that gets cited back at FDA in future comparable submissions: a device can be permanently implanted and still land in Class II if the special controls package is specific enough to actually manage the risk profile.

That's not a small point for anyone tracking where orthopedic implant classification is headed generally. FDA has been willing, in recent years, to move well-characterized implant categories out of the De Novo one-off process and into standing Class II regulations once enough real-world and bench data accumulates to define the risk boundaries. The same logic played out with the agency's March 2026 reclassification of optical diagnostic devices for melanoma detection and electrical impedance spectrometers (91 FR 14445), where a defined special controls package let FDA move a device out of the default Class III bucket. It's a pattern, not an isolated decision. It tells you something about how to argue your next De Novo or reclassification petition if you're sitting on a device that's currently stuck in Class III by default.

Effective Dates and What They Mean for You

The order was published June 5, 2026, and it's effective the same day, but that's the codification date, not the classification date. Per FDA's own notice, the classification itself was applicable on December 16, 2022 — the date of the original De Novo grant — and that's the date that matters if you're relying on this device type as a 510(k) predicate under 513(f)(2)(B)(i). There is no delayed compliance window or phase-in period attached to the classification itself, because a final order classifying a device type doesn't retroactively require anything of products already on the market under a prior clearance. What it does is set the rule for every submission filed from this point forward.

If you have a hemi-shoulder ceramic head/metallic stem device already in development, here's the practical sequencing:

1. Confirm your device fits the classified type. Read the device description in 21 CFR 888.3695 against your actual design. Cemented or uncemented, ceramic head, metallic stem, humeral hemi-arthroplasty. If your design deviates materially (a different articulating material, a total shoulder configuration rather than hemi), you may still need a De Novo request or a different predicate.
2. Map your existing test data against the seven special controls. Most orthopedic manufacturers already run fatigue, static strength, and wear testing as a matter of course. The gap is usually the clinical performance data category, so start there if you haven't already.
3. Build your adverse event taxonomy now, not at submission time. FDA named the categories: pain, device effects, surgical interventions, bone wear, osteolysis, loosening, migration, revision. Your clinical evaluation plan and your post-market surveillance plan should use the same taxonomy so the data is comparable across the product lifecycle.
4. File under 510(k), not De Novo, unless your device genuinely doesn't fit the classified type. The whole point of this order is to give you a predicate. Use it.

There's no petition deadline or comment period to track here. Final classification orders under 513(f)(2) aren't subject to notice-and-comment rulemaking the way a proposed rule would be. The De Novo grant itself was the substantive decision point; this order simply codifies it. If you disagree with the classification or the special controls as written, your avenue is a reclassification petition under 21 CFR 10.30 or 21 CFR 860.123, not a comment on this order.

Where This Intersects Your Quality Management System

A special controls list is only as good as the QMS that produces the evidence behind it. Under FDA's Quality Management System Regulation (21 CFR Part 820, harmonized with ISO 13485:2016 as of the QMSR's February 2, 2026 compliance date), your design controls, risk management file, and design history file are what actually generate the clinical and non-clinical data these special controls demand. The biocompatibility, sterility, and shelf-life testing named in the order aren't standalone activities, they're outputs of a design verification and validation process that should already be running under ISO 13485 clause 7.3 if your QMS is mature.

The risk management piece is worth calling out specifically. FDA's adverse event taxonomy for this device type, bone wear, osteolysis, loosening, migration, revision, maps almost directly onto the harms and hazardous situations your ISO 14971 risk analysis should already be tracking for an implanted orthopedic device. If your risk management file doesn't already speak the same language as this special controls list, that's the first document to update, not the test protocol. Getting the risk file aligned with FDA's stated risk categories now will save you a round of reviewer questions later, because the reviewer assigned to your 510(k) is going to compare your risk analysis against exactly these seven categories.

FAQ

Does this classification apply to devices already on the market? No. The order classifies the device type going forward for new submissions. It doesn't require manufacturers with existing clearances to refile, but any new 510(k) or De Novo request for a comparable device filed after June 5, 2026 is now evaluated against 21 CFR 888.3695 and its special controls.

Can I use this classification as a predicate for a 510(k)? Yes, that's the intended effect. Once a device type is classified into Class II with special controls, subsequent manufacturers of substantially equivalent devices generally use 21 CFR 807.81 (510(k) premarket notification) rather than filing their own De Novo request, provided their device matches the classified type's description and intended use.

What's the difference between a ceramic head/metallic stem hemi-shoulder device and a total shoulder prosthesis for classification purposes? A hemi-shoulder (hemi-arthroplasty) device replaces only the humeral head, articulating against the patient's native glenoid. A total shoulder prosthesis replaces both sides of the joint and is classified separately. The special controls in 21 CFR 888.3695 apply specifically to the hemi-arthroplasty configuration with a ceramic head and metallic stem, cemented or uncemented.

Do I need clinical data for a 510(k) citing this new classification as a predicate? FDA identified clinical performance data as one of the seven special controls for the device type, which means a 510(k) sponsor should expect to address it, either with sponsor-generated clinical data or a well-supported justification for relying on other valid scientific evidence. This is different from many orthopedic 510(k)s that clear on bench data alone, so budget for it early in your submission planning.

Where can I find the original De Novo decision this classification is based on? The final order references a De Novo request FDA received on February 8, 2022, from Tornier SAS for its Tornier Pyrocarbon Humeral Head, listed under product code HSD. The order itself, published at 91 FR 34152 under Docket No. FDA-2026-N-5830, is the authoritative source for the classification and special controls, and product code HSD is what to search for in FDA's device classification database.

If you're building a submission strategy around this classification, or trying to work out whether your risk management file already speaks FDA's language, that's exactly the kind of gap analysis worth doing before you start drafting test protocols rather than after. For a broader look at how a recent orthopedic classification action played out end to end, see our review of FDA's classification of resorbable calcium salt bone void filler devices, and for the risk management side of this work, see our guide to integrating ISO 14971 with your ISO 13485 QMS.

Last updated: 2026-09-02